Amendment to Offer Letter between the Company and David Humphrey dated February 23, 2021
EX-10.27 13 ex10-27.htm
February 23, 2021
|Re: ||Offer Letter February 11, 2021 Amendment|
This letter is to amend the Equity Award language of the fully executed February 11, 2021 Offer Letter from “Once the contemplated merger transaction closes you will be provided a stock option grant in a quantity representing 1.0% of the merged Company’s newly formed Equity Incentive Plan (the “Plan”). To “Once the contemplated merger transaction closes you will be provided a stock option grant of 275,000 shares of the merged Company’s newly formed Equity Incentive Plan (the “Plan”).
All other language in the February 11, 2021 Offer letter will remain the same.
|/s/ Lynn Kirkpatrick || |
|Lynn Kirkpatrick || |
|Chief Executive Officer || |
|/s/ David Humphrey || |
|Dave Humphrey || |
Ensysce Biosciences Inc.
7946 Ivanhoe Ave. Ste 201 - La Jolla, CA – 92037 www.ensysce.com